---
canonical_name: Astragalus
alternate_names: Huang Qi, Huangqi, Radix Astragali, Astragali Radix, Astragalus membranaceus, Astragalus mongholicus, Astragalus propinquus, milk vetch, Bei Qi
canonical_topic: Astragalus for Health & Longevity
short_topic_lc: astragalus
creation_date: 2026-0814-1131
creator_ai_fullname: Grok 4.5
---

# Astragalus for Health & Longevity  
<section id="top" markdown="1"></section>  
Evidence Review created on 08/14/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Grok 4.5  

**Also known as:** Huang Qi, Huangqi, Radix Astragali, Astragali Radix, Astragalus membranaceus, Astragalus mongholicus, Astragalus propinquus, milk vetch, Bei Qi  

<!-- Motivation written last, after all other sections, so it reflects the full scope of the review. -->  

  
## Motivation  

Astragalus is the dried root of a milk-vetch species long used in Chinese herbal practice as a daily tonic for stamina and recovery. The same root is now sold as capsules, teas, and branded extracts that claim to rebuild the protective tips of chromosomes and support healthy aging.  

Two stories sit side by side. Hospital trials, mostly from China and often using injected preparations, report help when the root is added to usual care for common age-related disease. Separate Western work on a purified root compound, sold as TA-65, reports longer chromosome end-caps without a matching gain in strength, walking distance, or inflammation. Much of that chromosome-tip literature is tied to the company that sells the extract.  

This review examines what oral and injected astragalus actually change in humans, how strong those signals are for a health- and longevity-oriented adult, and where product quality, stomach discomfort, and industry funding change the picture.  

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**  

  
## Recommended Reading  

High-level overviews of astragalus as a tonic, telomerase-active extract, and longevity candidate.  

<!-- Search 14 Aug 2026: WebSearch plus on-site search of foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com, lifeextension.com, and lifespan.io for astragalus / Huangqi / TA-65. Eligible high-level items: Lifespan.io trial write-up; Rhonda Patrick JRE #502 (TA-65/telomerase segment); Liu 2017 and Borowicz 2025 narrative reviews; Harley 2011 primary TA-65 report. Peter Attia site search returned "Nothing Found". Huberman Lab on-site search produced no dedicated episode. Chris Kresser site search returned no results (only a passing immune mention on a beta-glucan page). Life Extension Magazine has Andrews & West, Aug 2009, "Turning on Immortality: The Debate Over Telomerase Activation" (TA-65 mentioned; a telomerase-therapy debate, not an astragalus overview); other LE hits were product listings or brief mentions. Excluded Examine, ConsumerLab, systematic reviews, Wikipedia, forums, and mainstream news. -->  

- [Astragalus Supplement Lengthens Telomeres in the Middle-Aged](https://lifespan.io/astragalus-supplement-lengthens-telomeres-in-the-middle-aged/) - Anna Drangowska-Way  

  Walks through the 2024 de Jaeger randomized trial of an astragalus-based blend on telomere length in middle-aged adults, including limits of the multi-ingredient formula.  

- [Joe Rogan Experience #502 - Dr. Rhonda Patrick](https://www.foundmyfitness.com/episodes/jre-502) - Rhonda Patrick  

  Patrick reviews astragalus-derived TA-65, early human telomere data, and the concern that telomerase (the enzyme that rebuilds chromosome end-caps) activation could theoretically support pre-cancerous cells.  

- [Anti-Aging Implications of Astragalus Membranaceus (Huangqi): A Well-Known Chinese Tonic](https://pubmed.ncbi.nlm.nih.gov/29344421/) - Liu et al., 2017  

  Narrative review of Huangqi constituents and proposed effects on telomerase, vessels, brain aging, immunity, and cancer, spanning laboratory and early clinical work.  

- [Astragalus Membranaceus-Can It Delay Cellular Aging?](https://pubmed.ncbi.nlm.nih.gov/40284164/) - Borowicz & Jach, 2025  

  Updated narrative review of how astragalus constituents may influence cellular senescence and tissue aging, noting the absence of organism-level human lifespan data.  

- [A natural product telomerase activator as part of a health maintenance program](https://pubmed.ncbi.nlm.nih.gov/20822369/) - Harley et al., 2011  

  First published human TA-65 program report (commercial protocol; authors linked to Geron/TA Sciences, which sells the extract), describing immune-cell remodeling and fewer short telomeres.  

No dedicated Peter Attia, Andrew Huberman, or Chris Kresser overview was found. Attia, Huberman, and Kresser site searches returned no matching articles. Life Extension Magazine published a 2009 telomerase-activation debate that mentions TA-65; it is not an astragalus overview, so five more topic-specific sources are listed instead.  

  
## Grokipedia  

<!-- Direct grokipedia.com search 14 Aug 2026 for astragalus, Astragalus membranaceus, huangqi, and TA-65. Results were botanical species pages, a place-name town, and a Cycloastragenol constituent page. No dedicated medicinal Astragalus / Huangqi article. -->  

No dedicated Grokipedia article for medicinal astragalus was found as of 14 August 2026.  

  
## Examine  

<!-- Direct examine.com search 14 Aug 2026. Primary page: https://examine.com/supplements/astragalus/ (title Astragalus; last updated 1 Aug 2024). FAQ pages cover benefits and drawbacks. d-browser hit a Vercel checkpoint; page retrieved via d-proxy-1. -->  

- [Astragalus](https://examine.com/supplements/astragalus/)  

  Concise evidence map of claimed heart, metabolic, immune, and longevity effects, with dose notes for root, Danggui pairing, and isolated astragaloside IV.  

  
## ConsumerLab  

<!-- Direct consumerlab.com search 14 Aug 2026 for astragalus. The only dedicated-looking hit is a members-only CL Answer on branded TA-65 (updated 11 Sep 2025), a Q&A/FAQ rather than a primary product review. No separate generic-root product review. Paywalled CL Answer not used. -->  

No dedicated ConsumerLab article for astragalus was found as of 14 August 2026.  

  
## Systematic Reviews  

Pooled human and mixed clinical evidence on telomeres, glucose, heart failure, immunity, and diabetic kidney disease.  

<!-- PubMed 14 Aug 2026: (Astragalus membranaceus OR huangqi OR radix astragali OR astragaloside OR cycloastragenol OR TA-65) AND (systematic review[pt] OR meta-analysis[pt]). Title-restricted search returned 47 hits after excluding talus-bone false positives. Selected by recency, size, and longevity relevance. No standalone systematic review of oral-astragalus harm was found; safety is summarized inside the efficacy reviews below, especially Su 2025. -->  

- [Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/41286474/) - Su et al., 2025  

  Eight randomized trials (n = 750) of the branded saponin extract; telomeres lengthened, frailty and inflammation did not.  

- [The Efficacy and Safety of Astragalus as an Adjuvant Treatment for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis](https://pubmed.ncbi.nlm.nih.gov/37433206/) - Hong et al., 2024  

  Twenty trials (n = 953) of add-on astragalus versus usual diabetes care, with lower fasting glucose and glycated hemoglobin.  

- [Effect of Astragalus membranaceus on left ventricular remodeling in HFrEF: a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/38283626/) - Han et al., 2024  

  Nineteen trials (n = 1,565) of astragalus plus usual care for HFrEF (heart failure with reduced ejection fraction), reporting larger ejection fraction.  

- [The Effect of Astragalus on Humoral and Cellular Immune Response: A Systematic Review and Meta-Analysis of Human Studies](https://pubmed.ncbi.nlm.nih.gov/37952511/) - Zhang et al., 2023  

  Nineteen human studies (n = 1,094) pooled for cytokine and T-cell marker changes, with large effects and high heterogeneity.  

- [Astragalus membranaceus (Huang Qi) as adjunctive therapy for diabetic kidney disease: An updated systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/31034954/) - Zhang et al., 2019  

  Sixty-six trials (n = 4,785) of adjunctive preparations, mostly injections, showing less albuminuria (albumin leaking into urine) and lower creatinine.  

  
## Mechanism of Action  

The dried root of *Astragalus membranaceus* (also classified as *Astragalus mongholicus* or *Astragalus propinquus*) contains three chemical families: polysaccharides, saponins (astragaloside IV and its aglycone cycloastragenol), and flavonoids such as calycosin and formononetin.  

Polysaccharides act on innate and adaptive immunity. They engage pattern-recognition receptors on macrophages, natural killer cells, dendritic cells, and lymphocytes, raising cytokine output and shifting T-cell subset ratios. That same immune-facing activity is the basis both for proposed infection resistance and for concern in autoimmunity.  

Saponins drive the longevity claim. Cycloastragenol and related extracts, including branded TA-65, activate telomerase (the enzyme that rebuilds chromosome end-caps) at nanomolar concentrations in cultured keratinocytes, fibroblasts, and immune cells. Astragaloside IV also turns on AMPK (a cellular energy sensor) and dampens NF-κB (a switch for inflammatory genes), offering a metabolic and anti-inflammatory explanation that does not require telomere lengthening.  

Oral astragaloside IV is poorly absorbed (about 7% bioavailability in dogs) and is highly protein-bound. Cycloastragenol is better absorbed in rats (about 26%), undergoes first-pass hepatic metabolism, and is cleared by kidney and bile with possible enterohepatic recirculation (the compound re-enters the gut via bile). Human half-life remains poorly defined. Animal tissue distribution favors intestine, liver, and kidney. These properties explain why many Chinese hospital trials used intravenous Huangqi injection rather than oral root.  

  
## Historical Context & Evolution  

Astragalus root entered the Chinese materia medica as Huang Qi, the "yellow leader," a superior qi tonic for fatigue, poor appetite, spontaneous sweating, and frequent infection. Classical pairing with *Angelica sinensis* (Danggui Buxue Tang, 5:1) aimed to nourish both qi and blood. The herb was a daily resilience tonic, not a modern biomarker drug.  

Twentieth-century Chinese hospitals developed Huangqi injection and polysaccharide fractions for heart failure, kidney disease, and cancer-related fatigue. Western interest accelerated when Geron and later TA Sciences screened traditional herbs for telomerase activators and commercialized cycloastragenol-rich TA-65 around 2007. Early observational reports from that commercial program, and later small randomized trials, are the main source of the telomere claim. Many of those reports involve authors or funders with a direct financial interest in TA-65.  

Hospital meta-analyses of injection and formula products later reported gains in [heart-failure remodeling](https://pubmed.ncbi.nlm.nih.gov/38283626/), [diabetic kidney markers](https://pubmed.ncbi.nlm.nih.gov/31034954/), and [glucose](https://pubmed.ncbi.nlm.nih.gov/37433206/). Independent reviewers, including the [U.S. National Center for Complementary and Integrative Health (NCCIH)](https://www.nccih.nih.gov/health/astragalus), judged the same literature too biased and too heterogeneous to establish usefulness for any condition. Both the traditional tonic story and the modern telomerase story remain live; neither has been closed by a large, independent outcomes trial.  

  
## Expected Benefits  

<!-- Dedicated benefit-profile search 14 Aug 2026: PubMed for human trials and meta-analyses on telomeres, glucose, heart failure, immunity, diabetic kidney disease, idiopathic membranous nephropathy, cancer-related fatigue, post-stroke fatigue, allergic rhinitis, and metabolic syndrome; Examine FAQs; NCCIH fact sheet; Lifespan.io and ConsumerLab TA-65 pages. -->  

### Medium 🟩 🟩  

#### Leukocyte telomere length  

An astragalus-derived telomerase activator lengthens white-blood-cell telomeres in middle-aged and older adults. A [2025 meta-analysis](https://pubmed.ncbi.nlm.nih.gov/41286474/) of eight randomized trials (750 people) found a moderate increase, larger after age 60, without matching frailty or inflammation gains. Industry-funded trials reported bigger effects. TA Sciences, which sells TA-65, funded or employed authors on several key papers, including the [Salvador 2016](https://pubmed.ncbi.nlm.nih.gov/26950204/) year-long trial.  

**Magnitude:** Standardized mean difference (effect size in standard-deviation units) 0.47 for telomere length (95% CI [confidence interval] 0.31–0.62) in the TA-65 meta-analysis; one 12-month trial reported +530 bp (base pairs) at 250 U (TA-65 product units) versus −290 bp on placebo.  

### Low 🟩  

#### Adjunctive glycemic control in type 2 diabetes  

Add-on astragalus, often with metformin (a first-line glucose-lowering drug), lowered fasting glucose and glycated hemoglobin in a [20-trial meta-analysis](https://pubmed.ncbi.nlm.nih.gov/37433206/) of 953 adults. Most trials were small, unblinded Chinese hospital studies. The direction is consistent; the size is uncertain.  

**Magnitude:** Weighted mean difference (pooled average difference) −0.67 mmol/L fasting glucose and −0.93 percentage points glycated hemoglobin versus usual care alone.  

#### Adjunctive ventricular remodeling in reduced-ejection-fraction heart failure  

A [19-trial meta-analysis](https://pubmed.ncbi.nlm.nih.gov/38283626/) (1,565 people) of *Astragalus membranaceus* plus usual heart-failure care reported higher left-ventricular ejection fraction (share of blood ejected each beat) and smaller chambers. Many used injectable Huangqi, not oral capsules.  

**Magnitude:** Mean ejection-fraction gain +5.82 percentage points; end-diastolic diameter −4.05 mm versus conventional therapy alone.  

#### Immune-marker remodeling  

A [2023 systematic review](https://pubmed.ncbi.nlm.nih.gov/37952511/) of human studies shows lower proinflammatory cytokines (immune signaling proteins) and a higher CD4/CD8 ratio (helper versus killer T cells). A [post-infarct TA-65 trial](https://pubmed.ncbi.nlm.nih.gov/37086366/) raised lymphocytes and cut high-sensitivity C-reactive protein (hs-CRP).  

**Magnitude:** Pooled standardized mean difference −2.88 for proinflammatory cytokines and +2.46 for cellular-immunity markers; post-infarct hs-CRP 1.1 versus 2.9 mg/L at 12 months.  

#### Adjunctive albuminuria reduction in diabetic kidney disease  

An [updated 66-trial meta-analysis](https://pubmed.ncbi.nlm.nih.gov/31034954/) (4,785 people) found larger drops in urine albumin and serum creatinine when astragalus was added to usual care. Most evidence is short-term Huangqi injection. Oral-only data are thinner but move the same way.  

**Magnitude:** Standardized mean difference −2.05 for albuminuria and −1.85 for proteinuria; creatinine −14.8 µmol/L versus usual care.  

#### Adjunctive proteinuria reduction in membranous nephropathy (autoimmune kidney-filter disease)  

A [2023 meta-analysis](https://pubmed.ncbi.nlm.nih.gov/36862887/) of 50 trials (3,423 people) found larger drops in 24-hour urine protein and creatinine, and higher remission rates, when *Astragalus membranaceus* formulas were added to supportive or immunosuppressive care. Trials were Chinese hospital studies of mixed quality.  

**Magnitude:** Mean 24-hour urine protein −1.05 g; serum albumin +3.75 g/L; creatinine −6.24 µmol/L versus supportive or immunosuppressive care alone.  

#### Cancer-related fatigue ⚠️ Conflicted  

A [2025 meta-analysis](https://pubmed.ncbi.nlm.nih.gov/40302232/) of mixed *Astragalus membranaceus* preparations reported less cancer-related fatigue. A [2024 phase 2 PG2 trial](https://pubmed.ncbi.nlm.nih.gov/39465324/) of intravenous polysaccharides in breast-cancer chemotherapy missed its primary global-fatigue score. The findings conflict, likely because the analyses pooled different products, endpoints, and populations.  

**Magnitude:** Meta-analytic standardized mean difference −1.63 for fatigue scores; the PG2 trial found no significant between-group change in the fatigue global score.  

#### Adjunctive post-stroke fatigue  

A [2020 systematic review](https://pubmed.ncbi.nlm.nih.gov/31440984/) of 16 randomized trials (1,222 people) found lower fatigue scores and better daily-function scales when Huangqi formulas were added to usual stroke care. Trials were low quality with high bias risk.  

**Magnitude:** Fatigue and daily-function scores improved versus usual stroke care; the review does not report a single pooled effect-size figure.  

### Speculative 🟨  

#### Organismal longevity  

Telomere lengthening is treated as a proxy for slower cellular aging, but pooled TA-65 trials found no functional-aging benefit, and no human study has shown longer life. The claim is mechanistic only.  

#### Seasonal allergic rhinitis symptoms  

A small [six-week trial](https://pubmed.ncbi.nlm.nih.gov/19504468/) of an astragalus-containing herbal-mineral complex reduced rhinorrhea (runny nose) in weed-pollen allergy. The product was not astragalus alone, so attribution is uncertain.  

  
## Benefit-Modifying Factors  

- **Age:** Telomere lengthening in the TA-65 meta-analysis was larger after age 60 (standardized mean difference 0.63 versus 0.36). Older adults also carry more short telomeres and immunosenescent T cells (aged immune cells that no longer respond well), the compartments those trials targeted.  

- **Baseline kidney function:** Meta-regression in diabetic kidney-disease trials linked higher starting creatinine to a larger creatinine drop with Huangqi injection. People already near the conventional range have less room to move.  

- **Sex:** Premenopausal women in the PG2 breast-cancer trial showed a clearer fatigue signal than the mixed cohort. Telomere trials rarely stratify by sex despite known baseline length differences.  

- **Starting immune set-point:** CMV-positive (cytomegalovirus-infected) adults in the early TA-65 program lost more senescent CD8 T cells. People with autoimmune disease sit on the opposite side of that immune shift.  

- **Route and formula:** Injectable Huangqi and multi-herb decoctions dominate the heart, kidney, and glucose literature. Isolated oral saponin extracts dominate the telomere literature. Benefits do not transfer automatically across those forms.  

- **Industry funding:** Industry-funded TA-65 trials reported larger telomere effects than independent trials. That funding pattern is a modifier of apparent benefit size, not of biology itself.  

  
## Potential Risks & Side Effects  

<!-- Dedicated risk search 14 Aug 2026: PubMed for safety, adverse events, hepatotoxicity, autoimmune, hypersensitivity; NCCIH fact sheet; Drugs.com NPC monograph (updated 21 Oct 2025); Examine drawbacks FAQ; Su 2025 TA-65 safety analysis; Fu 2011 and Wang 2017 Huangqi-injection reviews. -->  

### Medium 🟥 🟥  

#### Gastrointestinal intolerance  

Nausea and abdominal discomfort are the most consistent adverse events in oral TA-65 trials. The [2025 meta-analysis](https://pubmed.ncbi.nlm.nih.gov/41286474/) of 487 safety-evaluable participants reported mild gastrointestinal toxicity without severe events over about 12 months. Whole-root studies often under-report adverse events, so this rate may be specific to concentrated saponin extracts.  

**Magnitude:** 12.4% mild gastrointestinal toxicity (nausea 7.1%, abdominal discomfort 5.3%) in the TA-65 safety pool; no severe events over 12 months.  

### Low 🟥  

#### Hypersensitivity reactions  

Oral products can cause rash. Injectable Huangqi, used in hospital trials, carries infusion-reaction risk typical of botanical intravenous products. [Heart-failure reviews](https://pubmed.ncbi.nlm.nih.gov/38283626/) found no extra total adverse events versus usual care, but they do not isolate allergy.  

**Magnitude:** Rash is listed in drug monographs without a reliable incidence; Huangqi-injection reviews report adverse-event rates similar to usual care (relative risk 0.86, 95% CI 0.25–2.96) but do not isolate allergy.  

#### Autoimmune disease worsening  

A [polysaccharide immunomodulation review](https://pubmed.ncbi.nlm.nih.gov/35713852/) reports that these fractions stimulate macrophages, natural killer cells, and T cells. NCCIH states that people with autoimmune disease should avoid astragalus because it might worsen symptoms; [Drugs.com](https://www.drugs.com/npc/astragalus.html) flags transplant and autoimmune settings. Controlled human flare-rate data are essentially absent.  

**Magnitude:** Not quantified in available studies. No controlled trial has measured autoimmune-flare incidence; the signal is mechanistic and from safety monographs.  

### Speculative 🟨  

#### Telomerase-related tumor promotion  

Telomerase is active in many cancers. Short-term TA-65 trials reported no oncogenic events out to 12 months; long-term cancer incidence is untested. The concern remains mechanistic.  

#### Fetal toxicity  

Animal work cited by NCCIH suggests fetal toxicity. Human pregnancy data are insufficient. This is a precaution, not a measured human risk.  

  
## Risk-Modifying Factors  

- **Autoimmune or transplant status:** Stimulatory polysaccharide activity is most relevant in lupus, rheumatoid arthritis, multiple sclerosis, and in people on calcineurin inhibitors (transplant anti-rejection drugs such as cyclosporine, tacrolimus) or other immunosuppressants.  

- **Route:** Intravenous Huangqi adds infusion-reaction risk that oral root does not share. Longevity users taking capsules are mainly exposed to gastrointestinal effects.  

- **Age:** Older adults in TA-65 trials had more telomere change and more chance to receive the extract; they also have higher background cancer incidence, which matters for the untested telomerase-cancer question.  

- **Sex:** No consistent sex difference in adverse-event rates is established. Pregnancy is a separate avoidance category because of animal fetal-toxicity signals.  

- **Baseline glucose and blood pressure:** Add-on glucose and pressure lowering, if real, raise hypoglycemia (low blood sugar) and hypotension (low blood pressure) risk when stacked with drugs that do the same.  

- **Product identity:** Non-medicinal *Astragalus* species (locoweeds) contain swainsonine and are not the same intervention. Species substitution is a quality-driven risk modifier.  

  
## Key Interactions & Contraindications  

- **Immunosuppressants (cyclosporine, tacrolimus, mycophenolate, high-dose corticosteroids):** Caution. Immune stimulation may oppose graft protection or flare control. Spacing does not remove the pharmacodynamic clash (opposing effects on the same immune pathway).  

- **Lithium:** Caution. Traditional diuretic activity can raise lithium levels. Monitor serum lithium if both are used; no established dose-offset schedule.  

- **Glucose-lowering drugs (metformin, sulfonylureas (older drugs that make the pancreas release insulin), insulin, SGLT2 inhibitors (gliflozins that dump glucose in urine)):** Monitor. Additive hypoglycemia is the clinical consequence. Huangqi injection altered gliquidone kinetics in a [pharmacokinetic study](https://pubmed.ncbi.nlm.nih.gov/24085486/).  

- **Antihypertensives (ACE inhibitors (lisinopril; block angiotensin-converting enzyme), ARBs (losartan; block the angiotensin receptor), amlodipine, hydrochlorothiazide):** Monitor. Possible additive blood-pressure lowering.  

- **Other immune stimulants (echinacea, medicinal mushrooms, beta-glucans):** Caution. Additive immune activation; relevant in autoimmunity.  

- **Glucose- and pressure-lowering supplements (berberine, cinnamon, hawthorn, beetroot):** Caution. Additive hypoglycemia or hypotension is possible when stacked with astragalus and with the matching drugs.  

- **Chemotherapy (anthracyclines (chemo drugs such as doxorubicin), cyclophosphamide):** Context-dependent. Hospital protocols use astragalus polysaccharides as an add-on for fatigue; this is not a license to self-combine with cytotoxic regimens.  

- **Over-the-counter NSAIDs (ibuprofen, naproxen, aspirin; nonsteroidal anti-inflammatory drugs):** Caution in monographs because they also affect immune tone; the clinical clash is poorly quantified.  

**Populations who should avoid Astragalus:**  

- Autoimmune disease (systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease)  
- Solid-organ or hematopoietic transplant, or current calcineurin-inhibitor immunosuppression  
- Pregnancy and lactation (animal fetal-toxicity signal; human data lacking)  
- Known allergy to *Astragalus* or its polysaccharide extracts  
- Unsupervised use of intravenous Huangqi injection outside a regulated clinical setting  

  
## Risk Mitigation Strategies  

- **Oral root or tested extract, not injection:** Avoids infusion-reaction risk tied to hospital Huangqi injection while remaining the form actually used for telomere protocols.  

- **Start low for concentrated saponins:** TA-65 trials used 10–50 mg (often 250 U); gastrointestinal toxicity rose in that pool. Protocols typically begin at the low end for 1–2 weeks.  

- **Species and third-party identity:** Use *A. membranaceus* / *A. mongholicus* products with astragaloside IV testing to avoid locoweed substitution and empty capsules.  

- **Immune-stimulant stacking in autoimmunity:** Not combining with echinacea, medicinal mushrooms, or interferon-type regimens avoids compounding polysaccharide activation that can worsen autoimmune disease.  

- **Glucose and pressure checks when on related drugs:** Weekly home glucose for 2–4 weeks and sitting/standing blood pressure catch additive lowering early.  

- **Hold before elective surgery if immune or glucose drugs are in play:** Reduces uncertainty around wound immunity and perioperative glucose; restart after the acute window.  

- **Pregnancy planning:** Stopping before conception addresses the animal fetal-toxicity signal that human trials have not cleared.  

  
## Therapeutic Protocol  

- **Traditional decoction:** Dried root 9–30 g/day, often as Danggui Buxue Tang (30 g astragalus with 6 g *Angelica sinensis*, 5:1). This is the classical qi-blood pair, not a telomerase protocol.  

- **Standardized oral extract:** Commercial root extracts are typically 250–500 mg, one to three times daily; labels vary by extraction ratio. Follow the stated astragaloside IV content when it is disclosed.  

- **Isolated astragaloside IV:** Examine cites 5–10 mg/day as the usual isolated-saponin range. Oral bioavailability is low, so milligram dose is not equivalent to injected Huangqi.  

- **TA-65 / cycloastragenol:** Trials used about 8–16 mg/day or 250–1,000 U, sometimes split. [Harley 2011](https://pubmed.ncbi.nlm.nih.gov/20822369/) reported nanomolar plasma levels after single 10–50 mg doses. TA Sciences is the commercial source for TA-65.  

- **Time of day:** Traditional use is morning, as a yang/qi tonic. No circadian outcome trial exists. Split doses are reasonable given first-pass metabolism and uncertain human half-life.  

- **Injectable PG2 / Huangqi:** Hospital astragalus polysaccharides 500 mg intravenously on selected chemotherapy days. This is a regulated drug-like use, not a longevity supplement protocol.  

- **Genetics:** No established dose rule for APOE4 (lipid-transport gene variant), MTHFR (folate-processing gene), or COMT (catecholamine-clearing enzyme).  

- **Sex and age:** No sex-specific oral dose. Older adults showed larger telomere change; they also warrant a slower start because of polypharmacy.  

- **Baseline labs:** Higher creatinine predicted a larger kidney-marker move; lower baseline glucose leaves less room and more hypoglycemia risk if drugs are stacked.  

- **Competing approaches:** Traditional Chinese medicine decoction (whole-root, multi-herb) versus isolated telomerase-active saponin. Neither is a default; they target different endpoints.  

  
## Discontinuation & Cycling  

- **Duration intent:** Traditional tonic use is long-term. Telomere trials ran 3–12 months. No evidence requires lifelong daily dosing for a lasting telomere gain.  

- **Withdrawal:** No recognized withdrawal syndrome. Immune-marker and telomere changes would be expected to drift back toward baseline after stopping; that return has not been mapped.  

- **Taper:** Not required for oral root or TA-65. People on glucose- or pressure-lowering drugs may need those drug doses reviewed when the herb is removed.  

- **Cycling:** No trial shows that cycling preserves efficacy. Some integrative clinics cycle immune herbs seasonally; that is practice pattern, not outcome data.  

- **After a flare or rash:** Stop rather than taper. Rechallenge is a specialist decision, especially after injection reactions.  

  
## Sourcing and Quality  

- **Correct species:** Medicinal material is *Astragalus membranaceus* / *Astragalus mongholicus* (*Astragalus propinquus*). Unrelated locoweed species contain swainsonine and are a different plant.  

- **Marker compounds:** Look for disclosed astragaloside IV or cycloastragenol content. "Astragalus 500 mg" without a marker says little about saponin dose.  

- **Third-party testing:** USP, NSF, or equivalent identity/purity testing matters because substitution and under-dosing are documented problems in herbal markets.  

- **TA-65 is proprietary:** The branded cycloastragenol extract is expensive and company-controlled. Generic cycloastragenol products are not automatically equivalent.  

- **Avoid unsupervised injections:** Huangqi injection is a Chinese patent medicine. It is not a dietary-supplement equivalent and is the form behind many hospital-trial effect sizes.  

- **Pairing herbs:** Danggui Buxue Tang is a defined 5:1 pair. Random "immune blend" products confound attribution and dose.  

  
## Practical Considerations  

- **Time to effect:** Immune-marker and symptom trials often run 4–12 weeks. Telomere change was measured at 3–12 months. Glucose and kidney-marker trials are usually weeks to a few months.  

- **Common pitfalls:** Treating telomere length as a proven longevity outcome; assuming injection-trial effect sizes apply to capsules; stacking several immune herbs; buying unspecified "astragalus" powder.  

- **Regulatory status:** In the United States, oral products are dietary supplements, not FDA-approved drugs. TA-65 has a new-dietary-ingredient file. Huangqi injection is not an over-the-counter longevity product.  

- **Cost:** Crude root is inexpensive; TA-65 is often hundreds of dollars per month. Insurers and health systems rarely cover either form, so that gap is a consumer cost, not a payer incentive.  

- **Access:** Root and generic extracts are widely sold. Independent cycloastragenol and hospital PG2 are narrower and, for PG2, clinical-only.  

  
## Interaction with Foundational Habits  

- **Sleep:** Direct effect none established. No trial shows astragalus disrupts or reliably improves sleep architecture. Concentrated extracts are commonly used earlier in the day when gastrointestinal discomfort would otherwise disturb sleep.  

- **Nutrition:** Indirect, potentiating with traditional pairing. Classical use is a cooked decoction, often with *Angelica sinensis*. Saponin extracts are commonly used with food when they cause nausea. No nutrient-depletion signal is established.  

- **Exercise:** Direct effect none established. Heart-failure trials that improved six-minute-walk distance used add-on Huangqi in diseased cohorts, not a hypertrophy-blunting or performance protocol in healthy trainers.  

- **Stress management:** Indirect, mechanistic only. Adaptogen language is traditional. Cortisol, heart-rate-variability, and validated stress-scale data in healthy adults are thin; the herb is not established as a substitute for sleep and load management.  

  
## Monitoring Protocol & Defining Success  

Before starting, a baseline panel establishes glucose, kidney, liver, blood-pressure, and inflammatory set-points so later change is visible against the person's own starting values. The same fasting blood work, urine albumin, and sitting-plus-standing blood pressure should be drawn under comparable conditions. Repeat that panel at 4–8 weeks to catch early glucose or pressure shifts, again at 3–6 months when telomere and immune-cell trials usually report, then every 6–12 months if use continues. Telomere-length assays are optional and method-dependent; they are not required to judge whether a longevity protocol is working. People on lithium, insulin, or anti-rejection or immune-suppressing drugs need the matching drug-level or disease-activity checks on that same cadence.  

Success is stable or improved energy and infection pattern without gastrointestinal intolerance, rash, or worse autoimmune symptoms, plus laboratory movement that matches the intended target (glucose, urine albumin, hs-CRP, or, if measured, telomere length). A longer telomere without a function change is a weak success definition.  

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |  
| --- | --- | --- | --- |  
| Fasting glucose | 70–85 mg/dL (3.9–4.7 mmol/L) | Tracks add-on glucose lowering | Conventional <100 mg/dL; fast 8–12 h |  
| HbA1c | 4.8–5.3% | 90-day glucose exposure | Glycated hemoglobin; conventional <5.7%; pair with fasting glucose |  
| hs-CRP | <0.7 mg/L | Inflammation; TA-65 secondary endpoint | High-sensitivity C-reactive protein; conventional often <3 mg/L; skip if acutely ill |  
| eGFR | >90 mL/min/1.73 m² | Kidney filter function | Estimated glomerular filtration rate; conventional ≥60; pair with urine albumin |  
| Urine albumin–creatinine ratio | <10 mg/g | Early kidney protein leak | Conventional <30 mg/g; morning sample |  
| ALT | <25 U/L (women), <30 U/L (men) | Liver safety | Alanine aminotransferase; conventional up to ~40–50 U/L |  
| Sitting and standing blood pressure | 110–120 / 70–80 mmHg | Additive pressure lowering | Measure both arms at baseline |  
| CBC with differential | Track change from own baseline | Lymphocyte remodeling; allergy signal | Complete blood count; no single optimal subset target; not a fasting test |  

- Energy and recovery after ordinary training or illness  
- Infection frequency and duration across a season  
- Gastrointestinal comfort after each dose  
- Joint, skin, or neurologic symptoms that could signal immune over-activation  
- For branded saponin use: whether any telomere report is accompanied by a real-world function change  

  
## Emerging Research  

- **TA-65 microvascular function:** [NCT05598359](https://clinicaltrials.gov/study/NCT05598359) (not yet recruiting; planned n = 180) tests whether 250 U TA-65 improves nitric-oxide-mediated skin blood flow and blood pressure in older adults, a functional test the telomere literature lacked.  

- **TA-65MD dose-finding:** [NCT02766790](https://clinicaltrials.gov/study/NCT02766790) (industry-sponsored; listed n = 500; status unknown, no results posted) compared four TA-65MD doses with placebo over nine months for immunosenescence and telomere length.  

- **Polysaccharide add-on in breast cancer:** Completed [NCT03314805](https://clinicaltrials.gov/study/NCT03314805) (PG2 500 mg IV (intravenous); n = 67) missed its primary fatigue endpoint; retrospective survival follow-up is registered as [NCT07601113](https://clinicaltrials.gov/study/NCT07601113).  

- **Telomere–function disconnect:** The [Su et al. 2025](https://pubmed.ncbi.nlm.nih.gov/41286474/) meta-analysis is the result most likely to weaken a longevity case if confirmed: longer telomeres without frailty or inflammation gains.  

- **Independent glucose and kidney trials:** [Hong et al. 2024](https://pubmed.ncbi.nlm.nih.gov/37433206/) and [Zhang et al. 2019](https://pubmed.ncbi.nlm.nih.gov/31034954/) would be strengthened—or shrunk—by large, blinded, oral-only trials outside single-country hospital networks.  

  
## Conclusion  

Astragalus is a traditional root tonic whose modern longevity case rests on two different products. Whole-root and hospital injections are the basis for glucose, kidney-protein, and heart-function signals. A purified root extract, sold as TA-65, is the basis for longer protective tips on white-cell chromosomes. Those chromosome-tip gains are the most coherent human finding for a longevity-oriented adult, and they are also the most commercially entangled: several key papers were funded or authored by people who sell the extract. The same pooled analysis that confirmed longer chromosome tips found no matching improvement in strength, walking, or inflammation.  

Changes in immune blood tests run in parallel. They can look like a more youthful blood profile, and they are the reason autoimmune disease and anti-rejection drugs after a transplant sit on the avoid list. Everyday oral use is mostly limited by nausea and stomach discomfort. Serious harm is not a prominent feature of short trials, but pregnancy, allergy, and unsupervised injection sit outside that reassurance.  

For a risk-aware adult already managing sleep, training, and metabolic basics, astragalus is a modest signal that depends on which product is used—not a settled longevity therapy and not a harmless everyday botanical in every immune setting. The evidence is strongest for a laboratory chromosome-tip change, thinner for disease add-on outcomes once study quality is counted, and empty for longer human life.  

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**